High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition
Metrics: PDF 1850 views | HTML 1685 views | ?
Jing Xiong1,2, Ying Liu3, Shengjun Luo1, Li Jiang1, Yang Zeng1, Zhixiong Chen1, Xiaobo Shi1, Bufan Lv1, Wei Tang1
1Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing
2Departmentof Urology and Andrology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China
3Department of Preventive Medicine, School of Public Health and Management, Hubei University of Medicine, Shiyan, Hubei Province, China
Wei Tang, email: email@example.com
Keywords: long non-coding RNAs, HEIRCC, renal cell carcinoma, prognosis, EMT
Received: June 30, 2016 Accepted: November 04, 2016 Published: December 24, 2016
Increasing evidence indicates that long non-coding RNAs (lncRNAs) have been associated with cancer development. However, the contributions of lncRNAs to renal cell carcinoma (RCC) remain poorly characterized. Here, we identified a novel lncRNA, termed HEIRCC, which was up-regulated in RCC tissues through lncRNA microarray analysis and subsequent validation in 60 RCC clinical specimens and cell lines. The high expression of HEIRCC is associated closely with the clinical pathology features such as larger tumor size, poor differentiation, lymphatic metastasis. In vitro assays revealed that HEIRCC knockdown could inhibit cell proliferation, trigger late apoptosis, suppress cell migration and invasion. We further demonstrated that depletion of HEIRCC reduce the epithelial to mesenchymal transition (EMT) program by regulating expression levels of EMT-associated markers in RCC cells. Thus, HEIRCC might be act as an important regulator of EMT in RCC progression and might be a novel therapeutic target for the advanced RCC therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.